Caelum Biosciences

.@AstraZeneca's @AlexionPharma has exercised its option to acquire Caelum, a company founded by @fortressbio, pursuant to the DOSPA in place between Fortress, Caelum, Alexion and the other parties thereto. More info: bit.ly/2XUfLjI $FBIO $AZN

The agreement also provides for additional potential payments to Caelum stockholders totaling up to $350 million, payable upon the achievement of regulatory and commercial milestones. Read more: bit.ly/3acNI20 $FBIO $AZN

.@AstraZeneca acquired Caelum for the agreed option exercise price of approximately $150 million. Distributions will be made to all existing Caelum stockholders. bit.ly/3acNI20 $FBIO $AZN

Caelum Biosciences, a company founded by Fortress Biotech, announces the closing of @AstraZeneca's acquisition of Caelum. bit.ly/3acNI20 $FBIO $AZN

.@AstraZeneca intends to advance and accelerate the Phase 3 development of CAEL-101 for light chain (AL) #amyloidosis. Read more: bit.ly/2XUfLjI $FBIO $AZN

The agreement also provides for additional potential payments to Caelum stockholders totaling up to $350 million, payable upon the achievement of regulatory and commercial milestones. bit.ly/2XUfLjI $FBIO $AZN

.@AstraZeneca's @AlexionPharma has exercised its option to acquire Caelum, a company founded by @fortressbio, pursuant to the DOSPA in place between Fortress, Caelum, Alexion and the other parties thereto. More info: bit.ly/2XUfLjI $FBIO $AZN

For additional information on new Phase 2 safety and tolerability data for CAEL-101 presented by Caelum and @AlexionPharma at #EHA2021, please visit: caelumbio.com/caelum-and-ale… $FBIO $ALXN

...and exploratory clinical biomarker data suggesting possible cardiac disease improvements and renal response among patients with cardiac or renal impairment at baseline, respectively. caelumbio.com/caelum-and-ale… $FBIO $ALXN

Caelum Biosciences and @AlexionPharma today announced new Ph 2 safety & tolerability data for CAEL-101, a potentially first in class amyloid fibril targeted therapy, in combination with standard of care therapy in patients with #ALamyloidosis. caelumbio.com/caelum-and-ale… $FBIO $ALXN

For more information on the Caelum CARES program, please visit: caelumbio.com/clinical-trial…

The Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101 in combination with SoC therapy in AL amyloidosis is currently underway. Read more: caelumbio.com/caelum-and-ale… $FBIO #EHA2021

Caelum Biosciences and @AlexionPharma announced that two abstracts on CAEL-101, a potentially first in class amyloid fibril targeted therapy, have been accepted for e-poster presentation at the @EHA_Hematology Congress 2021. More info: caelumbio.com/caelum-and-ale… #EHA2021 $ALXN $FBIO

Congrats to our COO, Susan Sobolov, on the successful launch of the new Connecticut chapter of @WomenInBio! The organization does great work to raise the profile of women in the life sciences. Learn more: newhavenbiz.com/article/women-… #womeninbio

This month we are recognizing the “Light the Night for Amyloidosis” campaign that drives awareness about amyloidosis by encouraging participants to light up their entryways with red bulbs during the month. For more info: amyloidosis.org/2021-light-the… @Amyloidosisfdn

In addition, throughout the month Caelum will be recognizing the “Light the Night for Amyloidosis” campaign that drives awareness about amyloidosis by encouraging participants to light up their entryways with red bulbs during the month. caelumbio.com/caelum-bioscie… #RareDisease

In honor of Amyloidosis Awareness Month and Rare Disease Day, Caelum has made several commitments to the amyloidosis community that seek to raise awareness, educate, support and empower patients diagnosed with amyloidosis and their families. caelumbio.com/caelum-bioscie…

We are proud to announce our collaboration with and support of the amyloidosis advocacy community as Amyloidosis Awareness Month begins. The campaign will spread awareness about amyloidosis and its symptoms to help prompt earlier diagnosis for patients. caelumbio.com/caelum-bioscie…